Meta10-19
Showing 1 - 25 of >10,000
Diffuse Large B-cell Lymphoma Trial in Hangzhou (Metabolically Armed CD19 CAR-T cells)
Recruiting
- Diffuse Large B-cell Lymphoma
- Metabolically Armed CD19 CAR-T cells
-
Hangzhou, Zhejiang, ChinaThe first affiliated hospital of medical college of zhejiang uni
Nov 1, 2023
B-cell Acute Lymphoblastic Leukemia Trial in Hefei (Metabolically Armed CD19 CAR-T cells)
Recruiting
- B-cell Acute Lymphoblastic Leukemia
- Metabolically Armed CD19 CAR-T cells
-
Hefei, Anhui, ChinaAnhui Provincial Hospital
Feb 17, 2023
Diffuse Large B-cell Lymphoma Trial in Hefei (Metabolically Armed CD19 CAR-T cells)
Recruiting
- Diffuse Large B-cell Lymphoma
- Metabolically Armed CD19 CAR-T cells
-
Hefei, Anhui, ChinaAnhui Provincial Hospital
Feb 9, 2023
Covid19, Respiratory Failure Trial in Frederick (Nebulised unfractionated heparin (UFH))
Recruiting
- Covid19
- Respiratory Failure
- Nebulised unfractionated heparin (UFH)
-
Frederick, MarylandFrederick Health Hospital
Feb 15, 2022
Patients With COVID-19 Trial in Tashkent (The drug "Rutan 0.1"., Basic treatment)
Completed
- Patients With COVID-19
- The drug "Rutan 0.1".
- Basic treatment
-
Tashkent, UzbekistanErkin Musabaev
May 15, 2023
Covid19 Trial in Buenos Aires, Cairo (Unfractionated heparin)
Recruiting
- Covid19
- Unfractionated heparin
-
Buenos Aires, Argentina
- +1 more
Feb 15, 2022
Chadox1 Ncov-19 Vaccine: Rapid Systematic Review and Meta
Active, not recruiting
- ChAdOx1 nCoV-19 Vaccine
- ChAdOx1 nCoV-19 vaccine
-
Assiut, EgyptAliae AR Mohamed-Hussein
Sep 18, 2021
SARS-CoV-2 Infection Trial in Hangzhou (Placebo, COVID-19 Vaccine (Vero Cell) ,Inactivated, COVID-19 mRNA Vaccine (ZSVG-02-O) 10
Recruiting
- SARS-CoV-2 Infection
- Placebo
- +4 more
-
Hangzhou, Zhejiang, ChinaShulan (Hangzhou) Hospital
Nov 7, 2023
Colonic Polyp Trial in Komagane (Experimental CS-EMR, Active Comparator HS-EMR)
Recruiting
- Colonic Polyp
- Experimental CS-EMR
- Active Comparator HS-EMR
-
Komagane, Nagano, JapanShowa Inan General Hospital
Jul 3, 2023
COVID-19, Infection Viral, Infections Trial in Bergen, Oslo (VB10.2129, VB10.2210)
Active, not recruiting
- COVID-19
- +2 more
- VB10.2129
- VB10.2210
-
Bergen, Norway
- +1 more
Jan 6, 2023
COVID-19 Trial in Sippy Downs (biological, combination product, other)
Not yet recruiting
- COVID-19
- Avacc 10
- +2 more
-
Sippy Downs, Queensland, AustraliaUniversity of the Sunshine Coast Clinical Trial Centre
Nov 1, 2022
Post-acute COVID-19 Syndrome Trial in Paris, Saint-Denis, Suresnes (Training in the management of functional disorders,
Not yet recruiting
- Post-acute COVID-19 Syndrome
- Training in the management of functional disorders
- Reimbursement of 3 long consultations
-
Paris, France
- +6 more
Oct 18, 2023
Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia
Recruiting
- Acute Lymphoblastic Leukemia, in Relapse
- +5 more
- CAR-20/19-T cells (1 x 10^5 CAR-20/19-T cells/kg)
- +4 more
-
Milwaukee, WisconsinMedical College of Wisconsin
Sep 22, 2022
SARS-CoV-2 Infection Trial in Bangkok (Full dose of Ad26.COV2. 5x10^10vp, Half dose of Ad26.COV2. 2.5x10^10vp)
Recruiting
- SARS-CoV-2 Infection
- Full dose of Ad26.COV2. 5x10^10vp
- Half dose of Ad26.COV2. 2.5x10^10vp
-
Bangkok, ThailandVaccine Trial Centre, Faculty of Tropical Medicine, Mahidol Univ
Sep 11, 2022
Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in Milwaukee (CAR-20/19-T cells (1.0 x10^5
Completed
- Lymphoma, Non-Hodgkin
- +3 more
- CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
- +3 more
-
Milwaukee, WisconsinFroedtert Hospital & Medical College of Wisconsin
Jun 26, 2022
COVID-19, Immunodeficiency Trial (Paxlovid 5 days, Paxlovid 10 days, Tixagevimab and Cilgavimab)
Not yet recruiting
- COVID-19
- Immunodeficiency
- Paxlovid 5 days
- +2 more
- (no location specified)
Oct 18, 2022
COVID-19 Trial in Birmingham, Leicester, Manchester (GRT-R910 10 mcg Dose (after AZ), GRT-R910 30 mcg Dose (after AZ), GRT-R910
Recruiting
- COVID-19
- GRT-R910 10 mcg Dose (after AZ)
- +3 more
-
Birmingham, United Kingdom
- +2 more
Aug 15, 2022
Covid19, SARS-CoV-2 Infection Trial in London (1x10^9 vp AZD1222, 5x10^9 vp AZD1222, 1x10^10 vp AZD1222)
Recruiting
- Covid19
- SARS-CoV-2 Infection
- 1x10^9 vp AZD1222
- +2 more
-
London, United KingdomImperial College London
Mar 11, 2022
COVID-19 Trial in Tashkent (Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells), Recombinant Novel
Recruiting
- COVID-19
- Omicron-Delta Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
- Recombinant Novel Coronavirus Protein Vaccine (CHO cells)
-
Tashkent, UzbekistanUzbekistan, Tashkent city, Said baraka street 10
Nov 11, 2022
Systemic Inflammatory Response Syndrome Trial in Madrid (Allogeneic thyTreg 5.000.000, Allogeneic thyTreg 10.000.000)
Recruiting
- Systemic Inflammatory Response Syndrome
- Allogeneic thyTreg 5.000.000
- Allogeneic thyTreg 10.000.000
-
Madrid, SpainHospital General Universitario Gregorio Marañon
Sep 22, 2023
Viral Dynamics of Omicron in Children
Completed
- SARS-CoV2 Infection, COVID-19
- Daily SARS-CoV-2 PCR Testing for 10 days
-
Toronto, Ontario, CanadaThe Hospital for Sick Children
Nov 25, 2022
CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Suzhou (ThisCART19A with Dose Level 1, ThisCART19A with Dose Level
Recruiting
- CAR
- +2 more
- ThisCART19A with Dose Level 1
- ThisCART19A with Dose Level 2
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Jan 18, 2023
COVID-19 Trial in Toulouse (Blood collection on admission and longitudinally, Blood collection on their first consultation and
Active, not recruiting
- COVID-19
- Blood collection on admission and longitudinally
- Blood collection on their first consultation and 10 to 14 days later
-
Toulouse, FrancePurpan University Hospital
May 17, 2022
Evaluation of Humoral Immunity Following COVID-19 in Pregnancy
Active, not recruiting
- COVID-19
- +2 more
- Blood sample
-
London, United Kingdom
- +1 more
Aug 8, 2022